In silico models for repeated-Dose Toxicity (RDT): Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for drugs

Fabiola Pizzo, Emilio Benfenati

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The preclinical stage in drug development requires the determination of repeated-dose toxicity (RDT) in animal models. The main outcome of RDT studies is the determination of the no observed adverse effect level (NOAEL) and the lowest observed adverse effect level (LOAEL). NOAEL is important since it serves to calculate the maximum recommended starting dose (MRSD) which is the safe starting dose for clinical studies in human beings. Since in vivo RDT studies are expensive and time-consuming, in silico approaches could offer a valuable alternative. However, NOAEL and LOAEL modeling suffer some limitations since they do not refer to a single end point but to several different effects and the doses used in experimental studies strongly influence the final results. Few attempts to model NOAEL and LOAEL have been reported. The available database and models for the prediction of NOAEL and LOAEL are reviewed here.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages163-176
Number of pages14
Volume1425
DOIs
Publication statusPublished - 2016

Publication series

NameMethods in Molecular Biology
Volume1425
ISSN (Print)10643745

Fingerprint

No-Observed-Adverse-Effect Level
Computer Simulation
Pharmaceutical Preparations
Animal Models
Databases

Keywords

  • Chronic toxicity
  • Drug safety
  • In silico models
  • LOAEL
  • NOAEL
  • Repeated-dose toxicity

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

In silico models for repeated-Dose Toxicity (RDT) : Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for drugs. / Pizzo, Fabiola; Benfenati, Emilio.

Methods in Molecular Biology. Vol. 1425 Humana Press Inc., 2016. p. 163-176 (Methods in Molecular Biology; Vol. 1425).

Research output: Chapter in Book/Report/Conference proceedingChapter

Pizzo, Fabiola ; Benfenati, Emilio. / In silico models for repeated-Dose Toxicity (RDT) : Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for drugs. Methods in Molecular Biology. Vol. 1425 Humana Press Inc., 2016. pp. 163-176 (Methods in Molecular Biology).
@inbook{53d2f0d26f704cd98e411f82cc6255f0,
title = "In silico models for repeated-Dose Toxicity (RDT): Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for drugs",
abstract = "The preclinical stage in drug development requires the determination of repeated-dose toxicity (RDT) in animal models. The main outcome of RDT studies is the determination of the no observed adverse effect level (NOAEL) and the lowest observed adverse effect level (LOAEL). NOAEL is important since it serves to calculate the maximum recommended starting dose (MRSD) which is the safe starting dose for clinical studies in human beings. Since in vivo RDT studies are expensive and time-consuming, in silico approaches could offer a valuable alternative. However, NOAEL and LOAEL modeling suffer some limitations since they do not refer to a single end point but to several different effects and the doses used in experimental studies strongly influence the final results. Few attempts to model NOAEL and LOAEL have been reported. The available database and models for the prediction of NOAEL and LOAEL are reviewed here.",
keywords = "Chronic toxicity, Drug safety, In silico models, LOAEL, NOAEL, Repeated-dose toxicity",
author = "Fabiola Pizzo and Emilio Benfenati",
year = "2016",
doi = "10.1007/978-1-4939-3609-0_9",
language = "English",
volume = "1425",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "163--176",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - In silico models for repeated-Dose Toxicity (RDT)

T2 - Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for drugs

AU - Pizzo, Fabiola

AU - Benfenati, Emilio

PY - 2016

Y1 - 2016

N2 - The preclinical stage in drug development requires the determination of repeated-dose toxicity (RDT) in animal models. The main outcome of RDT studies is the determination of the no observed adverse effect level (NOAEL) and the lowest observed adverse effect level (LOAEL). NOAEL is important since it serves to calculate the maximum recommended starting dose (MRSD) which is the safe starting dose for clinical studies in human beings. Since in vivo RDT studies are expensive and time-consuming, in silico approaches could offer a valuable alternative. However, NOAEL and LOAEL modeling suffer some limitations since they do not refer to a single end point but to several different effects and the doses used in experimental studies strongly influence the final results. Few attempts to model NOAEL and LOAEL have been reported. The available database and models for the prediction of NOAEL and LOAEL are reviewed here.

AB - The preclinical stage in drug development requires the determination of repeated-dose toxicity (RDT) in animal models. The main outcome of RDT studies is the determination of the no observed adverse effect level (NOAEL) and the lowest observed adverse effect level (LOAEL). NOAEL is important since it serves to calculate the maximum recommended starting dose (MRSD) which is the safe starting dose for clinical studies in human beings. Since in vivo RDT studies are expensive and time-consuming, in silico approaches could offer a valuable alternative. However, NOAEL and LOAEL modeling suffer some limitations since they do not refer to a single end point but to several different effects and the doses used in experimental studies strongly influence the final results. Few attempts to model NOAEL and LOAEL have been reported. The available database and models for the prediction of NOAEL and LOAEL are reviewed here.

KW - Chronic toxicity

KW - Drug safety

KW - In silico models

KW - LOAEL

KW - NOAEL

KW - Repeated-dose toxicity

UR - http://www.scopus.com/inward/record.url?scp=84990241075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990241075&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3609-0_9

DO - 10.1007/978-1-4939-3609-0_9

M3 - Chapter

AN - SCOPUS:84990241075

VL - 1425

T3 - Methods in Molecular Biology

SP - 163

EP - 176

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -